Recruiting
PHASE3
INTERVENTIONAL
NCT07035093
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.
Interventions
Name:
Retatrutide
Type:
DRUG
Description:
Administered SC
Name:
Placebo
Type:
DRUG
Description:
Administered SC
Primary Outcomes
Measure:
Change from Baseline in Pain Intensity Per Numeric Rating Scale
TimeFrame:
Baseline, up to 72 weeks
Description:
Measure:
Percent Change from Baseline in Body Weight
TimeFrame:
Baseline, up to 72 weeks
Description:
Trial Information
NCT ID
NCT07035093
Status
Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025